Report #2886391

Received Feb 22, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Unknown
Age: Age unknown
State: MN
Recovered: Unknown
Vaccinated: Feb 12, 2026
Onset: Feb 12, 2026
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
TDAP	TDAP (BOOSTRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	3BH5K	—

Symptoms (1)

Extra dose administered

Symptom narrative

administered Boostrix on 05JAN2026 and a 2nd Boostrix on 12FEB2026; This non-serious case was reported by a nurse via call center representative and described the occurrence of extra dose administered in a patient who received DTPa (Reduced antigen) (Boostrix) (batch number 3BH5K, expiry date 22-JAN-2027) for prophylaxis. Concomitant products included DIPHTHERIA VACCINE TOXOID;PERTUSSIS VACCINE ACELLULAR 3-COMPONENT;TETANUS VACCINE TOXOID (BOOSTRIX). On 12-FEB-2026, the patient received the 2nd dose of Boostrix. On 12-FEB-2026, an unknown time after receiving Boostrix, the patient experienced extra dose administered (Verbatim: administered Boostrix on 05JAN2026 and a 2nd Boostrix on 12FEB2026). The outcome of the extra dose administered was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 13-FEB-2026 The reporter requested recommendations on how to proceed after a resident had been administered an extra dose. The batch number was not provided upon follow- up with the reporter.

Other medications

BOOSTRIX